Copyright Reports & Markets. All rights reserved.

Global Bacterial Conjunctivitis Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Bacterial Conjunctivitis Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Bacterial Conjunctivitis Drugs Market Size Growth Rate by Product
      • 1.4.2 Fluoroquinolones
      • 1.4.3 Aminoglycosides
      • 1.4.4 Macrolides
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Bacterial Conjunctivitis Drugs Market Size Growth Rate by End User
      • 1.5.2 Infective (Viral and Bacterial)
      • 1.5.3 Allergic
      • 1.5.4 Irritant (Chemical)
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Bacterial Conjunctivitis Drugs Market Size
      • 2.1.1 Global Bacterial Conjunctivitis Drugs Revenue 2014-2025
      • 2.1.2 Global Bacterial Conjunctivitis Drugs Sales 2014-2025
    • 2.2 Bacterial Conjunctivitis Drugs Growth Rate by Regions
      • 2.2.1 Global Bacterial Conjunctivitis Drugs Sales by Regions
      • 2.2.2 Global Bacterial Conjunctivitis Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Bacterial Conjunctivitis Drugs Sales by Manufacturers
      • 3.1.1 Bacterial Conjunctivitis Drugs Sales by Manufacturers
      • 3.1.2 Bacterial Conjunctivitis Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Bacterial Conjunctivitis Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Bacterial Conjunctivitis Drugs Revenue by Manufacturers
      • 3.2.1 Bacterial Conjunctivitis Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Bacterial Conjunctivitis Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Bacterial Conjunctivitis Drugs Price by Manufacturers
    • 3.4 Bacterial Conjunctivitis Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Bacterial Conjunctivitis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Bacterial Conjunctivitis Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Bacterial Conjunctivitis Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Bacterial Conjunctivitis Drugs Sales by Product
    • 4.2 Global Bacterial Conjunctivitis Drugs Revenue by Product
    • 4.3 Bacterial Conjunctivitis Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Bacterial Conjunctivitis Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Bacterial Conjunctivitis Drugs by Countries
      • 6.1.1 North America Bacterial Conjunctivitis Drugs Sales by Countries
      • 6.1.2 North America Bacterial Conjunctivitis Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Bacterial Conjunctivitis Drugs by Product
    • 6.3 North America Bacterial Conjunctivitis Drugs by End User

    7 Europe

    • 7.1 Europe Bacterial Conjunctivitis Drugs by Countries
      • 7.1.1 Europe Bacterial Conjunctivitis Drugs Sales by Countries
      • 7.1.2 Europe Bacterial Conjunctivitis Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Bacterial Conjunctivitis Drugs by Product
    • 7.3 Europe Bacterial Conjunctivitis Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Bacterial Conjunctivitis Drugs by Countries
      • 8.1.1 Asia Pacific Bacterial Conjunctivitis Drugs Sales by Countries
      • 8.1.2 Asia Pacific Bacterial Conjunctivitis Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Bacterial Conjunctivitis Drugs by Product
    • 8.3 Asia Pacific Bacterial Conjunctivitis Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Bacterial Conjunctivitis Drugs by Countries
      • 9.1.1 Central & South America Bacterial Conjunctivitis Drugs Sales by Countries
      • 9.1.2 Central & South America Bacterial Conjunctivitis Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Bacterial Conjunctivitis Drugs by Product
    • 9.3 Central & South America Bacterial Conjunctivitis Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Bacterial Conjunctivitis Drugs by Countries
      • 10.1.1 Middle East and Africa Bacterial Conjunctivitis Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Bacterial Conjunctivitis Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Bacterial Conjunctivitis Drugs by Product
    • 10.3 Middle East and Africa Bacterial Conjunctivitis Drugs by End User

    11 Company Profiles

    • 11.1 Santen Pharmaceutical
      • 11.1.1 Santen Pharmaceutical Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Santen Pharmaceutical Bacterial Conjunctivitis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Santen Pharmaceutical Bacterial Conjunctivitis Drugs Products Offered
      • 11.1.5 Santen Pharmaceutical Recent Development
    • 11.2 Perrigo
      • 11.2.1 Perrigo Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Perrigo Bacterial Conjunctivitis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Perrigo Bacterial Conjunctivitis Drugs Products Offered
      • 11.2.5 Perrigo Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck Bacterial Conjunctivitis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck Bacterial Conjunctivitis Drugs Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Bayer
      • 11.4.1 Bayer Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bayer Bacterial Conjunctivitis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bayer Bacterial Conjunctivitis Drugs Products Offered
      • 11.4.5 Bayer Recent Development
    • 11.5 Akorn
      • 11.5.1 Akorn Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Akorn Bacterial Conjunctivitis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Akorn Bacterial Conjunctivitis Drugs Products Offered
      • 11.5.5 Akorn Recent Development

    12 Future Forecast

    • 12.1 Bacterial Conjunctivitis Drugs Market Forecast by Regions
      • 12.1.1 Global Bacterial Conjunctivitis Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Bacterial Conjunctivitis Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Bacterial Conjunctivitis Drugs Market Forecast by Product
      • 12.2.1 Global Bacterial Conjunctivitis Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Bacterial Conjunctivitis Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Bacterial Conjunctivitis Drugs Market Forecast by End User
    • 12.4 North America Bacterial Conjunctivitis Drugs Forecast
    • 12.5 Europe Bacterial Conjunctivitis Drugs Forecast
    • 12.6 Asia Pacific Bacterial Conjunctivitis Drugs Forecast
    • 12.7 Central & South America Bacterial Conjunctivitis Drugs Forecast
    • 12.8 Middle East and Africa Bacterial Conjunctivitis Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Bacterial Conjunctivitis Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). 
      The development of multi-drug resistant variants, which is resulting in the augmented use of drugs, is expected to boost market growth during the forecast period. Microbes such as Streptococcus or Staphylococcus are responsible for bacterial conjunctivitis. These microbes change themselves chemically to develop resistance to the drugs. Since this resistance develops due to the irrational use of antibiotics, it may lead to severe complications in the body of the patients. Patients are thus expected to take up more medications such as corticosteroids and higher doses of antibiotics for the treatment of such diseases. This augmented use of drugs like corticosteroids and antibiotics for the treatment of bacterial conjunctivitis will propel the prospects for growth in this market.
      The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.
      The rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.
      The global Bacterial Conjunctivitis Drugs market is valued at 430 million US$ in 2018 and will reach 320 million US$ by the end of 2025, growing at a CAGR of -3.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bacterial Conjunctivitis Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Bacterial Conjunctivitis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bacterial Conjunctivitis Drugs in these regions.
      This research report categorizes the global Bacterial Conjunctivitis Drugs market by top players/brands, region, type and end user. This report also studies the global Bacterial Conjunctivitis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Santen Pharmaceutical
      Perrigo
      Merck
      Bayer
      Akorn

      Market size by Product
      Fluoroquinolones
      Aminoglycosides
      Macrolides
      Others
      Market size by End User
      Infective (Viral and Bacterial)
      Allergic
      Irritant (Chemical)

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Bacterial Conjunctivitis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Bacterial Conjunctivitis Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Bacterial Conjunctivitis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Bacterial Conjunctivitis Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Bacterial Conjunctivitis Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bacterial Conjunctivitis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now